| HOME >> BIOLOGY >> TECHNOLOGY |
Non-GAAP
operating margin 24% 26% 25% 28%
GAAP net income 7,267 8,647 (16%) 29,648 21,772 36%
GAAP net margin 11% 25% 15% 22%
Adjustments
Share-based
compensation 3,128 1,475 9,526 6,261
Amortization
of acquired
intangible assets 3,950 -- 10,532 --
Deferred tax
impact related
to acquired
intangible assets (1,548) -- (4,129) --
Non-GAAP net income 12,797 10,122 26% 45,577 28,033 63%
Non-GAAP net margin 19% 30% 23% 29%
GAAP net income 7,267 8,647 29,648 21,772
Add back:
Depreciation
and amortization 8,797 2,724 23,594 6,223
Interest income
(expenses), net (148) (1,334) (644) (589)
Income taxes 826 178 (1,147) 507
EBITDA 16,742 10,215 64% 51,451 27,913 84%
Adjustments
Share-based
compensation 3,128 1,475 9,526 6,261
Adjusted EBITDA 19,870 11,690 70% 60,977 34,174 78%
Income
attributable
to holders of
ADS (Non- GAAP):
Basic 12,797 8,039 45,577 16,690
Diluted 12,797 8,069 45,577 16,690
Basic earnings
per ADS (Non-GAAP) 0.20 0.18 0.72 0.54
Diluted
earnings per
ADS (Non-GAAP) 0.18 0.15 0.63 0.44
Weighted
average ADS
outstanding -
basic 64,531,068 44,774,893 63,010,497 30,860
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2008 PR Newswire. All rights reserved |